NDANASALSPRAY, METERED
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
NASONEX 24HR ALLERGY (mometasone furoate) by PharmaIN is corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. First approved in 2022.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NASONEX 24HR ALLERGY is a metered nasal spray containing mometasone furoate, a corticosteroid indicated for allergic rhinitis. It works by inhibiting phospholipase A2, thereby suppressing the biosynthesis of inflammatory mediators such as prostaglandins and leukotrienes. The drug delivers sustained anti-inflammatory, antipruritic, and vasoconstrictive activity via intranasal application.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30/100), suggesting stable commercial operations and potential for defensive market positioning.
Mechanism of Action
corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Started Jul 2026
188 enrolled
Asthma
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
Started May 2023
200 enrolled
Asthma
Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial
Started Sep 2022
20 enrolled
Acute Rhinosinusitis
Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma
Started Jun 2021
24 enrolled
Asthma
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
Started Dec 2015
2,216 enrolled
Asthma
Worked on NASONEX 24HR ALLERGY at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.